Trials / Conditions / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

19 registered clinical trials studyying Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab NCT07097363	University of Washington	Phase 2
Recruiting	ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL NCT06693830	Hua-Jay J Cherng, MD	N/A
Recruiting	A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma NCT06486051	Malaghan Institute of Medical Research	Phase 2
Recruiting	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Trea NCT06015880	National Cancer Institute (NCI)	Phase 1
Recruiting	P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies NCT06014762	Poseida Therapeutics, Inc.	Phase 1
Recruiting	Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19 NCT06238648	Academic and Community Cancer Research United	Phase 2
Recruiting	A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409	IDP Discovery Pharma S.L.	Phase 1 / Phase 2
Unknown	Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma NCT05786989	Chongqing University Cancer Hospital	Phase 4
Suspended	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diag NCT04799275	National Cancer Institute (NCI)	Phase 2 / Phase 3
Active Not Recruiting	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma NCT04257578	University of Washington	Phase 1 / Phase 2
Recruiting	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Agg NCT04231877	University of Washington	Phase 1
Terminated	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients Wit NCT04205838	Jonsson Comprehensive Cancer Center	Phase 2
Active Not Recruiting	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lympho NCT03984448	National Cancer Institute (NCI)	Phase 2 / Phase 3
Withdrawn	Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients NCT03850028	University Medical Center Groningen	N/A
Completed	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large NCT03742258	Northwestern University	Phase 1
Active Not Recruiting	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large NCT03656835	Ohio State University Comprehensive Cancer Center	N/A
Terminated	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02706405	Fred Hutchinson Cancer Center	Phase 1
Approved For Marketing	Expanded Access Program for Epcoritamab NCT05733650	Genmab	—